言語を選択

HGF

HGF 詳細

英語名	Hepatocyte growth factor	市販薬剤の数	1
治験薬の数	7	ターゲットの別称	EC 3.4.21.7，Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor)，EC 3.4.21，HGF，Hepatopoietin-A，Scatter factor，Hepatocyte Growth Factor (Hepapoietin A，Scatter Factor)，Fibroblast-Derived Tumor Cytotoxic Factor，Lung Fibroblast-Derived Mitogen，SF，Deafness， Autosomal Recessive 39，Hepatopoietin A，DFNB39，F-TCF，HGFB，Hepatocyte Growth Factor，HPTA
研究＆開発段階	Approved

英語名	Hepatocyte growth factor
ターゲットの別称	EC 3.4.21.7，Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor)，EC 3.4.21，HGF，Hepatopoietin-A，Scatter factor，Hepatocyte Growth Factor (Hepapoietin A，Scatter Factor)，Fibroblast-Derived Tumor Cytotoxic Factor，Lung Fibroblast-Derived Mitogen，SF，Deafness， Autosomal Recessive 39，Hepatopoietin A，DFNB39，F-TCF，HGFB，Hepatocyte Growth Factor，HPTA
市販薬剤の数	1
治験薬の数	7
研究＆開発段階	Approved

HGF 製品リスト

属性
Protein (4)Kits (1)
製品ライブラリ
オンライン (5)
種
Human (5)
タグ
His Tag (1)Fc Tag (1)- (1)Tag Free (2)
マーカー
Unconjugated (4)- (1)

製品番号	種	発現システム	製品説明
HOT HGF-H5218	Human	HEK293	Human HGF Protein, premium grade
HOT HGF-H5253	Human	HEK293	Human HGF Protein, Fc Tag (MALS verified)
HOT HGF-H52H3	Human	HEK293	Human HGF Protein, His Tag, low endotoxin (MALS verified)
CRS-B012	Human	-	Human HGF ELISA Kit
GMP-HGFH28	Human	HEK293	GMP Human HGF Protein

総数量5

HGFバックグランド

Hepatocyte growth factor (HGF) is a paracrine cellular growth, motility and morphogenic factor. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration. In addition, HGF has been implicated in a variety of cancers, including of the lungs, pancreas, thyroid, colon, and breast.

HGF分子の別称

HGF,HPTA,SF

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Fosgonimeton	NDX-1017; ATH-1017; ATH 1017	Phase 3 Clinical	M3 Biotechnology	Alzheimer Disease; Dementia; Lewy Body Disease; Parkinson Disease	詳細
RGL-2102	RGL-2102; RGL2102	Phase 3 Clinical	Shanghai Regenelead Therapies Co Ltd	Diabetic Foot; Ischemia; Ulcer; Wound Infection	詳細
Ficlatuzumab	AV-299; SCH-900105	Phase 3 Clinical	Aveo	Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colonic Neoplasms; Glioblastoma; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Multiple Myeloma; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Respiratory Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck	詳細
Umikibart	YYB-101; NOV-1105; CLM-101	Phase 2 Clinical	YooYoung Pharmaceutical Co Ltd	Colorectal Neoplasms; Solid tumours	詳細
ATH-1020	ATH-1020	Phase 1 Clinical	Athira Pharma Inc	Nerve Degeneration	詳細
ATH-1105	ATH-1105	Phase 1 Clinical	Athira Pharma Inc	Amyotrophic Lateral Sclerosis; Frontotemporal Dementia	詳細
Microbiome-optimized autologous stem cell therapy (Biotech Holdings)		Clinical	Biotech Holdings	Peripheral Vascular Diseases	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Beperminogene perplasmid	AMG-0001-01; AMG-0001; DS-992; TREAT-HGF	Approved	Anges Mg, Osaka University	Collategene	Japan	Peripheral Arterial Disease; Ischemia	Anges Inc, null	2019-03-01	Arterial Occlusive Diseases; Atherosclerosis; Foot Ulcer; Ischemia; Peripheral Arterial Disease; Peripheral Vascular Diseases; Ulcer; Vascular Diseases	詳細